.webp)
Pharma giant strengthens technology leadership with seasoned CTO who brings 20+ years of digital transformation expertise from Accenture and Johnson & Johnson.
Biocon has named Mandar Ghatnekar as its new Chief Technology Officer with the responsibility of driving its digital transformation and enterprise technology strategy forward. The pharmaceutical industry leader's appointment is an indication of its continued support for technological advancement of the technology backbone of its Bengaluru operations, including biosimilar development and provision of global health care services.
Ghatnekar comes to the position with vast experience from his former job as Global Head of IT & Digital Transformation of Biocon Biologics Ltd., where his responsibilities included managing the post-merger IT integration process and implementing artificial intelligence and cloud computing solutions for the company. Ghatnekar was a major contributor to the improvements of the company’s supply chain management, procurement processes, and biosimilars development. A veteran in enterprise technology and digital transformation with more than two decades of professional experience, Ghatnekar earned his Master's in Computer Science from the University of Pune.
Prior to his current role at Biocon, Ghatnekar served as a leader at Accenture and Johnson & Johnson, where he created the field of digital strategy consulting for pharma organizations. He managed projects involving predictive analytics for manufacturing at Accenture. His stint at Johnson & Johnson was marked by efforts to build a global data platform and technology offerings based on compliance, leading to innovations in drug delivery and cost reduction.
The selection of Ghatnekar at Biocon is in line with its strategic priority in exploiting the biotech-healthtech convergence in India to speed up development and create personalized medicine products. Business Honor believes that his vision will allow him to integrate technology within the entire organization so that Biocon can improve its regulatory compliance as well as succeed in the $150 billion biosimilars market by 2030.
About the Author
Sandra Kelembeth is an experienced content writer with a keen eye for detail. She creates engaging, clear, and informative content that simplifies complex concepts and empowers readers to make more informed choices.
.webp)
